Tobias A.W. Holderried

Author

Also Known As

Holderried, Tobias, T A W Holderried, T. Holderried, Tobias A W Holderried, Tobias A. Holderried, Tobias A. W. Holderried, Tobias A.W. Holderried, Tobias AW Holderried, Tobias Albert Wilhelm Holderried, Tobias Holderried

109

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

University Hospital Bonn Heinrich Heine University Düsseldorf Universität Hamburg University Medical Center Hamburg-Eppendorf Harvard University

About

Tobias A.W. Holderried is an author at University Hospital Bonn specializing in medicine, immunology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.1K
2	Cell Biology	7	7	839
3	Health Sciences	1	1	400
4	Cellular Therapies	1	1	27
5	Hepatology	1	1	400

Tobias A.W. Holderried

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
Ly-6C <sup>high</sup> Monocytes Depend on Nr4a1 to Balance Both Inflammatory and Reparative Phases in the Infarcted Myocardium Ingo Hilgendorf, Louisa M.S. Gerhardt, Timothy C. Tan, Circulation Research	2014	528
Stable inhibitory activity of regulatory T cells requires the transcription factor Helios Hye‐Jung Kim, R. Anthony Barnitz, Taras Kreslavsky, Science	2015	411
On-demand erythrocyte disposal and iron recycling requires transient macrophages in the liver Igor Theurl, Ingo Hilgendorf, Manfred Nairz, Nature Medicine InflammationIron DeficiencyOn-demand Erythrocyte DisposalHepatologyHealth Sciences	2016	400
Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells Güllü Görgün, Tobias A.W. Holderried, David Zahrieh, Journal of Clinical Investigation Lymphocyte DevelopmentImmunologyCd4 T Cell ResponsesT CellsImmune System	2005	297
Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients Susanne M. Rittig, Maik Haentschel, Katrin J Weimer, Molecular Therapy	2010	218
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial Hartmut Goldschmidt, K. Elias, Uta Bertsch, The Lancet Haematology Transplantation-eligible PatientsHematological MalignancyPart 1TransplantationMedicine	2022	142
Innate Response Activator B Cells Aggravate Atherosclerosis by Stimulating T Helper-1 Adaptive Immunity Ingo Hilgendorf, Igor Theurl, Louisa M.S. Gerhardt, Circulation	2014	130
Eμ- <i>TCL1</i> mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction Güllü Görgün, Alan G. Ramsay, Tobias A.W. Holderried, Proceedings of the National Academy of Sciences	2009	125
Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma Tobias A.W. Holderried, Luka de Vos, Emma Bawden, Clinical Epigenetics	2019	83
Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy Susanne M. Rittig, Maik Haentschel, Katrin J Weimer, OncoImmunology ImmunologyImmunoeditingPathologyImmunotherapeuticsImmunotherapy	2015	66

Page 1